Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19766698 | 0.88 | MAPT (0.62) | CETPMAPTKMT2AMEN1POLB | |
| SCHEMBL702988 | 0.85 | MAPT (0.58) | CETPMAPTKMT2AMEN1POLB | |
| SCHEMBL29620186 | 0.85 | MAPT (0.58) | CETPMAPTKMT2AMEN1POLB | |
| SCHEMBL30186214 | 0.85 | HSD17B10 (0.61) | MAPTCYP1A2CYP2C9CYP2C19HSD17B10 | |
| SCHEMBL29625706 | 0.83 | CYP1A2 (0.71) | CETPMAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL23515386 | 0.83 | CYP1A2 (0.71) | CETPMAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL29625680 | 0.82 | MAPT (0.47) | CETPMAPTKMT2AMEN1POLB | |
| SCHEMBL24953211 | 0.82 | MAPT (0.47) | CETPMAPTKMT2AMEN1POLB | |
| SCHEMBL24953242 | 0.81 | CETP (0.71) | CETPMAPTKMT2AMEN1POLB | |
| SCHEMBL29625758 | 0.81 | CETP (0.71) | CETPMAPTKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | SHANGHAI EAST HOSPITAL (CN) | 2023-01-19 | — | — | US | disclosed |
| WO-2021114313-A1 | ION CHANNEL ANTAGONISTS/BLOCKERS AND USES THEREOF | SHANGHAI EAST HOSPITAL (CN) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | CACNA1F, CACNA1S, CACNA1D | CETP 1967/4885MAPT 2678/4885KMT2A 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.